Skip to content
You can now search across every topic, entity and event.What's new
UK Startups and Innovation
13APR

Tropic Biosciences raises $105m from Norwich

2 min read
17:59UTC

A gene-editing tropical crops company closed an oversubscribed Series C outside the London-Oxford-Cambridge corridor. Temasek and Corteva Catalyst are on the cap table.

← Back to State capital floods in, seed money drainsJump to analysis ↓
TechnologyDeveloping
Key takeaway

A Norwich gene-editing company raised $105m, proving deep-tech capital can reach beyond the Golden Triangle.

Tropic Biosciences, a Norwich-based gene-editing company focused on tropical crops, closed an oversubscribed $105m Series C co-led by Forbion and Corteva Catalyst 1. Temasek, Just Climate, and IQ Capital also participated. The round is one of the few large UK deep-tech raises located outside the London, Oxford, and Cambridge corridor.

Tropic works on gene-editing staple crops (bananas, coffee, rice) for disease resistance and yield improvement. The investor mix reflects the company's position at the intersection of food security and biotechnology: Corteva is a global agricultural sciences company, Temasek is Singapore's sovereign wealth fund with a strong food security mandate, and Just Climate focuses on climate-positive investment.

Norwich's presence in the round is notable. The city hosts the John Innes Centre and the Earlham Institute, two of the UK's strongest plant and genomic science institutions, but the region has not historically attracted venture capital at this scale. Tropic's success suggests that deep-tech companies rooted in genuine research clusters can raise internationally even without a London address, provided the science is strong and the commercial application (food supply resilience) has a clear global buyer.

Deep Analysis

In plain English

Tropic Biosciences is a company based in Norwich that uses gene-editing (not genetic modification in the traditional sense) to develop crop varieties that are more disease-resistant, drought-tolerant, or longer-lasting. It works primarily on tropical crops like bananas and coffee. It raised $105m, meaning investors gave it that money in exchange for a share of the company. Unusually for UK deep tech investment, which clusters heavily around London, Cambridge, and Oxford, this company is in Norwich. Its success demonstrates that significant investment can reach UK tech companies outside the traditional funding hubs.

What could happen next?
  • Opportunity

    Tropic's raise demonstrates that deep-tech companies outside the London-Oxford-Cambridge corridor can attract major international institutional investors, potentially encouraging more regional deep-tech investment.

Sources:The Next Web
Mentions:Tropic Biosciences →Forbion →Corteva Catalyst →Temasek →Spark Capital →Cambridge →Just Climate →John Innes Centre →Wyss Institute →
First Reported In

Update #1 · State capital floods in, seed money drains

The Next Web· 13 Apr 2026
Read original →
Different Perspectives
Institute of Physics
Institute of Physics
The Institute has long argued STFC's national-laboratory infrastructure, not its grant programmes, is the binding constraint on UK physics output, and warns mothballing capacity like Clara removes capability that cannot be rebuilt on a four-year cycle. It represents the discovery-science community absorbing the reallocation the Bank's equity cheques do not touch.
Helsing
Helsing
The Munich-headquartered defence-AI firm chose Plymouth over Continental sites for a £350m manufacturing plant building underwater surveillance gliders, alongside its record raise. Its choice of postcode signals confidence in UK manufacturing capacity for defence hardware even as it looks abroad for the capital financing that hardware.
Dragoneer Investment Group, Lightspeed Venture Partners and Iconiq
Dragoneer Investment Group, Lightspeed Venture Partners and Iconiq
The three US growth-capital firms backed Helsing's $1.8bn round at an $18bn valuation, more than doubling the mark set only a year earlier, with demand reportedly exceeding the capital on offer. Their money, not a UK sovereign vehicle, is what funds the Plymouth plant, extending a pattern of foreign capital underwriting British defence-hardware manufacturing this cycle.
British Business Bank
British Business Bank
The Bank wrote its largest-ever direct life-sciences cheque into Alchemab and added a £6.5bn SME lending guarantee the same week UKRI confirmed the STFC cuts. It is deploying an April mandate change letting it lead venture rounds and invest directly up to £60m per company, treating equity extension rounds and small-business debt as newly within its risk appetite.
Daphni
Daphni
The Paris seed fund joined Speedinvest and three UK backers in Astral Systems' GBP23m Series A for modular fusion reactors, one of the round's five European co-investors betting on lab-to-market fusion ahead of any working commercial reactor. Unlike CuspAI's all-foreign cap table, this round kept a UK lead investor in Mercia Ventures.
EQT
EQT
EQT, appointed by the European Innovation Council to run the EUR5bn Scaleup Europe Fund, entered advanced talks for a further CuspAI stake reported on 3 July, the fund's first pursuit of a UK-founded winner. A closed deal would put EU sovereign capital, not a UK vehicle, on the cap table of a company Britain's own funds passed over.